187 related articles for article (PubMed ID: 29165546)
1. Will liquid biopsies become our fluid transition to personalized immunotherapy?
Wauters E; Vansteenkiste J
Ann Oncol; 2018 Jan; 29(1):11-13. PubMed ID: 29165546
[No Abstract] [Full Text] [Related]
2. Circulating tumor DNA: Solid data from liquid biopsies.
Schrump DS
J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1132-1133. PubMed ID: 28629844
[No Abstract] [Full Text] [Related]
3. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.
Boffa DJ; Graf RP; Salazar MC; Hoag J; Lu D; Krupa R; Louw J; Dugan L; Wang Y; Landers M; Suraneni M; Greene SB; Magaña M; Makani S; Bazhenova L; Dittamore RV; Nieva J
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1139-1145. PubMed ID: 28446544
[No Abstract] [Full Text] [Related]
4. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
5. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
Dhar M; Wong J; Che J; Matsumoto M; Grogan T; Elashoff D; Garon EB; Goldman JW; Sollier Christen E; Di Carlo D; Kulkarni RP
Sci Rep; 2018 Feb; 8(1):2592. PubMed ID: 29416054
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the benefit of non-small-cell lung cancer immunotherapy.
Ludmir EB; McCaw ZR; Grossberg AJ; Wei LJ; Fuller CD
Lancet; 2019 Nov; 394(10212):1904. PubMed ID: 31777387
[No Abstract] [Full Text] [Related]
8. "Electronic Nose" Predicts Immunotherapy Response.
Abbasi J
JAMA; 2019 Nov; 322(18):1756. PubMed ID: 31714968
[No Abstract] [Full Text] [Related]
9. Quantifying the benefit of non-small-cell lung cancer immunotherapy - Authors' reply.
Mok TSK; Zhang J; Lopes G
Lancet; 2019 Nov; 394(10212):1904-1905. PubMed ID: 31777386
[No Abstract] [Full Text] [Related]
10. Immunotherapy in lung cancer: the chemotherapy conundrum.
Buddharaju LNR; Ganti AK
Chin Clin Oncol; 2020 Aug; 9(4):59. PubMed ID: 32036674
[No Abstract] [Full Text] [Related]
11. Monitoring immunotherapy outcomes with circulating tumor DNA.
Goldberg SB; Patel AA
Immunotherapy; 2018 Sep; 10(12):1023-1025. PubMed ID: 30185140
[No Abstract] [Full Text] [Related]
12. Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
Lu J; Han B
Technol Cancer Res Treat; 2018 Jan; 17():1533033818801809. PubMed ID: 30244652
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
Jain D; Sukumar S; Mohan A; Iyer VK
Cytopathology; 2018 Dec; 29(6):550-557. PubMed ID: 29938855
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply.
Ferrara R; Caramella C; Besse B
JAMA Oncol; 2019 May; 5(5):744. PubMed ID: 30896761
[No Abstract] [Full Text] [Related]
15. Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer.
Tsai EB; Pomykala K; Ruchalski K; Genshaft S; Abtin F; Gutierrez A; Kim HJ; Li A; Adame C; Jalalian A; Wolf B; Garon EB; Goldman JW; Suh R
Radiology; 2018 Apr; 287(1):326-332. PubMed ID: 29232184
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
Steuer CE; Ramalingam SS
J Clin Oncol; 2018 Mar; 36(7):631-632. PubMed ID: 29337637
[No Abstract] [Full Text] [Related]
17. [Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer].
Li Y; Chen J
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):585-589. PubMed ID: 31422587
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
Smit EF; van den Heuvel MM
Lancet; 2016 Apr; 387(10030):1795-6. PubMed ID: 26972842
[No Abstract] [Full Text] [Related]
19. Fiber-Optic Array Scanning Technology (FAST) for Detection and Molecular Characterization of Circulating Tumor Cells.
Ao Z; Liu X
Methods Mol Biol; 2017; 1634():235-246. PubMed ID: 28819856
[TBL] [Abstract][Full Text] [Related]
20. Evidence for circulating cancer stem-like cells and epithelial-mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy.
Mirza S; Jain N; Rawal R
Tumour Biol; 2017 Mar; 39(3):1010428317695915. PubMed ID: 28347243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
